Home News & Events Events

Future Events

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

The abstracts providing information on the design of the Company’s recently initiated Phase III clinical trial with lead product ATIR101™ and Phase I/II clinical trial with ATIR201™, have been accepted for poster presentation on March 27 and 28, 2017 respectively at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France.

Poster presentations:
Date:Monday March 27, 2017 from 9:00 – 18:30 CET
Title: Introduction of the HATCY study: A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101 with post-transplant cyclophosphamide in patients with a hematologic malignancy
Poster: A171
You can find the abstract here.

Date: Tuesday March 28, 2017 from 9:00 – 18:00 CET
Title: An exploratory, open-label study to evaluate the safety and feasibility of ATIR201, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment), as adjuvant treatment to a T-cell depleted haploidentical hematopoietic stem cell transplantation in patients with beta-thalassemia major
Poster: B276
You can find the abstract here.

Full abstracts are also available on the EBMT website. In addition, the abstracts will be published in the supplement edition of Bone Marrow Transplantation.

26 - 29, March, 2017, Marseille, France

KBC Securities, Biotech & Healthcare Conference

29, March, 2017, Brussels, Belgium

5th Annual Cell & Gene Investor Day

27, April, 2017, Boston (MA), USA

21st Training Course on Hemopoietic Stem Cell Transplantation

As a sponsor in 2017, Kiadis Pharma will support the ESH-EBMT 21st Training Course on Haemopoietic Stem Cell Transplantation to take place on May 04 – May 06, 2017 – Saggart (Dublin), IRELAND.

Every year, the ESH-EBMT Training Course provides a comprehensive training in all aspects of autologous and allogeneic stem cell transplantation and comprises a mixture of formal lectures, case presentations by attendees and faculty, meet-the-expert breakfasts and dinner table discussions. For each topic an explanation of the basic principles is provided, followed by development of the subject through to the most recent advances in understanding and management. The objective of the course is to give opportunity to the attendees to have close contact and lively interaction with the teachers and the group in a nice setting.

4 - 6, May, 2017, Dublin, Ireland